Your browser doesn't support javascript.
loading
High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study.
Frade-Sosa, Beatriz; Ponce, Andrés; Ruiz-Esquide, Virginia; García-Yébenes, Maria Jesús; Morlá, Rosa; Sapena, Nuria; Ramirez, Julio; Azuaga, Ana Belen; Sarmiento, Juan Camilo; Cañete, Juan D; Gomez-Puerta, Jose A; Sanmarti, Raimon.
Afiliación
  • Frade-Sosa B; Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
  • Ponce A; Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
  • Ruiz-Esquide V; Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
  • García-Yébenes MJ; Instituto de Salud Musculoesquelética, 28045 Madrid, Spain.
  • Morlá R; Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
  • Sapena N; Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
  • Ramirez J; Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
  • Azuaga AB; Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
  • Sarmiento JC; Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
  • Cañete JD; Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
  • Gomez-Puerta JA; Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
  • Sanmarti R; Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
Diagnostics (Basel) ; 12(1)2022 Jan 13.
Article en En | MEDLINE | ID: mdl-35054349
BACKGROUND: We examined whether high-sensitivity CRP (hsCRP) reflected the inflammatory disease status evaluated by clinical and ultrasound (US) parameters in RA patients receiving IL-6 receptor antibodies (anti-IL-6R) or JAK inhibitors (JAKi). METHODS: We conducted a cross-sectional study of patients with established RA receiving anti-IL-6R (tocilizumab, sarilumab) or JAKi (tofacitinib, baricitinib). Serum hsCRP and US synovitis in both hands were measured. Associations between hsCRP and clinical inflammatory activity were evaluated using composite activity indices. The association between hsCRP and US synovitis was analyzed. RESULTS: 63 (92% female) patients (42 anti- IL-6R and 21 JAKi) were included, and the median disease duration was 14.4 (0.2-37.5) years. Most patients were in remission or had low levels of disease. Overall hsCRP values were very low, and significantly lower in anti-IL-6R patients (median 0.04 mg/dL vs. 0.16 mg/dL). Anti-IL-6R (82.4%) patients and 48% of JAKi patients had very low hsCRP levels (≤0.1 mg/dL) (p = 0.002). In the anti-IL-6R group, hsCRP did not correlate with the composite activity index or US synovitis. In the JAKi group, hsCRP moderately correlated with US parameters (r = 0.5) but not clinical disease activity, and hsCRP levels were higher in patients with US synovitis (0.02 vs. 0.42 mg/dL) (p = 0.001). CONCLUSION: In anti-IL-6R RA-treated patients, hsCRP does not reflect the inflammatory disease state, but in those treated with JAKi, hsCRP was associated with US synovitis.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Diagnostics (Basel) Año: 2022 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Diagnostics (Basel) Año: 2022 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza